전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,135 programs
AntibodyLimited DatastaleTianjin Medical University Canc…Preclinical

Enituzumab injection+Abesili tablets+Anastrozole tablets (Enituzumab injection+Abesili tablets+Anastrozole tablets)

Advanced HR+ HER2 Negative Breast Carcinoma · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#AdvancedHR+HER2NegativeBreastCar+1
Trials 1Status Active
AntibodyLimited DatastaleFox Chase Cancer CenterPhase 2

pembrolizumab (Keytruda, Epacadostat + pembrolizumab)

Recurrent/ Metastatic Endometrial Carcinoma · Recurrent/ Metastatic Endometrial Carcin

#RecurrentMetastaticEndometrialCa#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Discontinued
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-DCs (EphA2-targeted CAR-DCs)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-T Cells (EphA2-targeted CAR-T Cells)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells (Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells)

Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleBoehringer IngelheimPhase 1

Ezabenlimab (Ezabenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#Boehringer
Trials 1Status Recruiting
CGTLimited DatastaleUTC Therapeutics Inc.Phase 1

FAST LACO-Stim CDH17 CAR-T (FAST LACO-Stim CDH17 CAR-T)

Biliary Tract Cancer; Colorectal Carcinoma · Biliary Tract Cancer

#BiliaryTractCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

FGFR4-CAR T Cells (FGFR4-CAR T Cells)

Rhabdomyosarcoma · Rhabdomyosarcoma

#Rhabdomyosarcoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleWashington Research FoundationPhase 1

FH FOLR1 ST CAR T-cells (FH FOLR1 ST CAR T-cells)

Advanced Osteosarcoma; Recurrent Osteosarcoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

FL33-03 CAR-T therapy (FL33-03 CAR-T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleMedical University of ViennaPhase 2

atezolizumab (Tecentriq, FMT combined with Atezolizumab plus Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Medical
Trials 1Status Active
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

FOLR1 CAR T-cells (FOLR1 CAR T-cells)

Recurrent Childhood Acute Myeloid Leukemia; Refractory Childhood Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleFate TherapeuticsPhase 1

Allogenic CAR NK cells with BCMA expression (FT576, FT576 (Allogenic CAR NK cells with BCMA expression))

Multiple Myeloma; Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

1 x 10^8 cells per dose (FT836 CAR T cells, FT836 CAR T cells (1 x 10^8 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

3 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (3 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

up to 9 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (up to 9 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBenjamin TomlinsonPhase 1

Fully human anti CD19 CAR-T Cell Dose (Fully human anti CD19 CAR-T Cell Dose)

Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

GB5005 CART (GB5005 CART)

Non-hodgkin Lymphoma; Refractory Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHe HuangPhase 2

GC022F CAR-T cells (GC022F CAR-T cells)

Relapsed and Refractory; Lymphoid Hematological Malignancies · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active

39 / 57 pages

← PreviousNext →